RECRUITINGINTERVENTIONAL

PALLAS Laser for Skin Diseases

Study of the Effectiveness of the PALLAS Laser in the Treatment of Skin Diseases That Respond Well to UV Light

About This Trial

The primary objective of this study is to get clinical experiences with the PALLAS laser in the treatment of skin conditions that respond well to UV light (vitiligo, psoriasis, alopecia areata, atopic dermatitis). The secondary objective is to assess how user-friendly is the Pallas laser in the treatment of skin diseases. The patient in the trial will receive UVB laser treatment (2 treatments per week for up to 3 months). The treatments will be carried out by the doctors participating in the trial. The treatment takes approximately 10 minutes per session, and can last up to 3 months per patient. Photographic documentation of the lesions to be treated and the lesions treated is taken at the start of the examination and then once a month. At the end of the study, the patient rates the treatment and improvement on a Patient Satisfaction Scale.

Who May Be Eligible (Plain English)

Who May Qualify: 1. The subject understands the information provided, gives willing to sign a consent form to participate in the study and is deemed by the investigator to be able to participate, 2. a skin condition that is expected to respond well to targeted UVB treatment, 3. a signed consent form. Who Should NOT Join This Trial: 1. Patient under 18 years of age, 2. pregnancy 3. epilepsy, 4. fever, infectious diseases, 5. the patient is within one month or currently enrolled in another clinical trial. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language

Inclusion Criteria: 1. The subject understands the information provided, gives informed consent to participate in the study and is deemed by the investigator to be able to participate, 2. a skin condition that is expected to respond well to targeted UVB treatment, 3. a signed consent form. Exclusion Criteria: 1. Patient under 18 years of age, 2. pregnancy 3. epilepsy, 4. fever, infectious diseases, 5. the patient is within one month or currently enrolled in another clinical trial.

Treatments Being Tested

DEVICE

UVB laser treatment

In clinical practice, 311 nm ultraviolet B (UVB) phototherapy is often used to treat various skin conditions. In 1996, the 308 nm xenon chloride excimer laser was developed for the treatment of psoriasis. In the last decades, excimer treatment has been incorporated into international therapeutic protocols for the treatment of psoriasis alongside conventional 311 nm UVB therapies. In the present study, the investigators aim to gain experience with a UVB laser (Pallas) operating at a wavelength of 311 nm. The CE-marked Pallas UVB laser will be used for the same indications as the 308 nm excimer laser. The procedure is not new, but the significance of this study lies in its potential to provide us with experience using this device for targeted UVB treatment.

Locations (1)

University of Szeged, Albert Szent-Györgyi Clinical Centre, Department of Dermatology and Allergology

Szeged, Csongrád-Csanád Vármegye, Hungary